| Cell Line         | Species  | Kindly provided by                                                                 |
|-------------------|----------|-------------------------------------------------------------------------------------|
| 1411H             | Human    | Dr. Matthew Murray (University of Cambridge, Cambridge, United Kingdom)             |
| GO72              | Human    | Dr. Christoph Oing (University Hospital Eppendorf, Hamburg, Germany)                |
| GCT72             | Human    | Dr. Thomas Müller (University Clinic for Internal Medicine IV, Hematology/Oncology, Medical Faculty of Martin Luther University Halle-Wittenberg, Halle (Saale), Germany) |
| HUVEC             | Human    | Prof. Dr. Gerhard Fritz (Institute of Toxicology, Medical Faculty, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany) |
| HVHF2             | Human    | Clinic for dermatology, University Hospital Düsseldorf, Germany                     |
| JAR               | Human    | ATCC, #HTB-144                                                                      |
| JEG-3             | Human    | ATCC, #HTB-36                                                                      |
| JURKAT            | Human    | Prof. Dr. Rüdiger Sorg (Institute for Transplantation Diagnostics and Cell Therapeutics, Faculty of Medicine, Heinrich-Heine-University, Düsseldorf, Germany) |
| MPAF              | Human    | Dr. Michael Peitz (Life & Brain, Department of Reconstructive Neurobiology, Bonn, Germany) |
| NCCIT             | Human    | Dr. Christoph Ding University Hospital Eppendorf, Hamburg, Germany                   |
| THP-1             | Human    | Prof. Dr. Peter Just (Department of Respiratory Medicine, University of Cape Town, South Africa) |

| Cell line         | Entity               | Medium                        | Supplements                                      |
|-------------------|----------------------|-------------------------------|--------------------------------------------------|
| 1411H             | Embryonal carcinoma / Yolk-sac tumor | DMEM (1x) + GlutaMAX - I    | 10 % FBS, 1 % P/S (10,000 U), 1 % L-Glutamin (200 mM) |
| GO72              | Yolk-sac tumor       | RPMI Medium 1640 (1x)        | 10 % FBS, 1 % P/S (10,000 U), 1 % L-Glutamin (200 mM) |
| GCT72             | Embryonal carcinoma | RPMI Medium 1640 (1x)        | 10 % FBS, 1 % P/S (10,000 U), 1 % L-Glutamin (200 mM) |
| HUVEC             | Endothelial cells    | Endothelial Cell Growth Medium 2 | Manufacturers provided supplements             |
| HVHF2             | Fibroblasts          | DMEM (1x) + GlutaMAX - I    | 10 % FBS, 1 % P/S (10,000 U), 1 % L-Glutamin (200 mM), 1% non-ess. aa (100x) |
| JAR               | Choriocarcinoma      | DMEM (1x) + GlutaMAX - I    | 10 % FBS, 1 % P/S (10,000 U), 1 % L-Glutamin (200 mM) |
| JEG-3             | Choriocarcinoma      | DMEM (1x) + GlutaMAX - I    | 10 % FBS, 1 % P/S (10,000 U), 1 % L-Glutamin (200 mM) |
| JURKAT            | Monocytes            | RPMI Medium 1640 (1x)        | 10 % FBS, 1 % P/S (10,000 U), 1 % L-Glutamin (200 mM) |
| MPAF              | Fibroblasts          | DMEM (1x) + GlutaMAX - I    | 10 % FBS, 1 % P/S (10,000 U), 1 % L-Glutamin (200 mM), 1% non-ess. aa (100x) |
| NCCIT             | Embryonal carcinoma | RPMI Medium 1640 (1x)        | 10 % FBS, 1 % P/S (10,000 U), 1 % L-Glutamin (200 mM) |
| TCam-2            | Seminoma             | RPMI Medium 1640 (1x)        | 10 % FBS, 1 % P/S (10,000 U), 1 % L-Glutamin (200 mM) |
| THP-1             | Monocytes            | RPMI Medium 1640 (1x)        | 10 % FBS, 1 % P/S (10,000 U), 1 % L-Glutamin (200 mM) |

Dr. Thomas Müller (University Clinic for Internal Medicine IV, Hematology/Oncology, Medical Faculty of Martin Luther University Halle-Wittenberg, Halle (Saale), Germany)